Overview

Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg

Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan quinapril hydrochloride 40 mg tablets compared to Parke-Davis Accupril® 40 mg tablets following a single, oral 40 mg (1 x 40 mg) dose under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Mylan Pharmaceuticals
Treatments:
Quinapril